Expert Assessment of In Vitro Potency Assays for Monoclonal Antibody Preparations

INTRODUCTION. The quality control of biotechnological medicinal products requires a range of biological assay procedures. The development of bioassays for potency determination is a complex process that should comply with the requirements set forth in regulatory standards. For adequate reproducibility, bioassays should be properly described in draft product specification files.

AIM. This study aimed to summarise the recommendations for developing in vitro bioassays for potency determination of monoclonal antibody preparations and for describing these bioassays in product specification files.

DISCUSSION. This article describes the Fab- and Fc-associated biological activi­ty mechanisms of monospecific and bispecific monoclonal antibodies. The article covers in vivo and in vitro methods used to study these mechanisms, with emphasis on the reporter gene assay. The article formulates the concept and analyses the components of a holistic analytical system that is necessary for bioassay development. A well-designed analytical procedure can minimise the influence of critical factors on the test results and reduce the risks of both random and systematic errors. This article presents an estimation of the significance of detailed description of critical procedure parameters in the draft product specification file for a monoclonal antibody.

CONCLUSIONS. A bioassay for the determination of potency should reflect the mecha­nism of action of the medicinal product and should provide the lowest possible variability and the highest possible ease of use. An adequate analytical procedure with appropriate analytical conditions can reduce the risk of obtaining invalid quality control results.

1. Khalimova AA, Orlov AS, Taube AA. Analysis of biopharmaceutical manufacturing localisation in Russia considering the country of origin of active pharmaceutical ingredients. Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation. 2024;14(1):53–61 (In Russ.). https://doi.org/10.30895/1991-2919-2024-14-1-53-61

2. Gogesch P, Dudek S, van Zandbergen G, Waibler Z, Anzaghe M. The role of Fc receptors on the effectiveness of therapeutic monoclonal antibodies. Int J Mol Sci. 2021;22(16):8947. https://doi.org/10.3390/ijms22168947

3. Wang X, An Z, Luo W, Xia N, Zhao Q. Molecular and functional analysis of monoclonal antibodies in support of biologics development. Protein Cell. 2018;9(1):74–85. https://doi.org/10.1007/s13238-017-0447-x

4. Alt N, Zhang TY, Motchnik P, Taticek R, Quarmby V, Schlothauer T, et al. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals. 2016;44(5):291–305. https://doi.org/10.1016/j.biologicals.2016.06.005

5. Gao X, Wang W, Tesar D, Wei B, Eschelbach J, Kelley RF, Jiang G. An approach to bioactivity assessment for critical quality attribute identification based on antibody-antigen complex structure. J Pharm Sci. 2021;110(4):1652–60. https://doi.org/10.1016/j.xphs.2020.12.027

6. Joshi S, Rathore AS, Krull IS. Analytical characterization of biotherapeutic products, Part II: The analytical toolbox. LCGC North Am. 2018;36(11):814–22.

7. Rathore AS, Dash R. Tools for functional assessment of biotherapeutics. LCGC North Am. 2021;39(6):272–77.

8. Cedeño-Arias M, Sánchez-Ramírez J, Blanco-Santana R, Rengifo-Calzado E. Validation of a flow cytometry based binding assay for evaluation of monoclonal antibody recognizing EGF receptor. Sci Pharm. 2011;79(3):569–81. https://doi.org/10.3797/scipharm.1104-18

9. Kamen L, Myneni S, Langsdorf C, Kho E, Ordonia B, Thakurta T, et al. A novel method for determining antibody-dependent cellular phagocytosis. J Immunol Methods. 2019;468:55–60. https://doi.org/10.1016/j.jim.2019.03.001

10. Dash R, Singh SK, Chirmule N, Rathore AS. Assessment of functional characterization and comparability of biotherapeutics: a review. AAPS J. 2021;24(1):15. https://doi.org/10.1208/s12248-021-00671-0

11. Heinrich L, Tissot N, Hartmann DJ, Cohen R. Comparison of the results obtained by ELISA and surface plasmon resonance for the determination of antibody affinity. J Immunol Methods. 2010;352(1–2):13–22. https://doi.org/10.1016/j.jim.2009.10.002

12. Register AC, Tarighat SS, Lee HY. Bioassay development for bispecific antibodies-challenges and opportunities. Int J Mol Sci. 2021;22(10):5350. https://doi.org/10.3390/ijms22105350

13. Wang L, Yu C, Wang J. Development of reporter gene assays to determine the bioactivity of biopharmaceuticals. Biotechnol Adv. 2020;39:107466. https://doi.org/10.1016/j.biotechadv.2019.107466

14. Chen W, Pandey M, Sun H, Rolong A, Cao M, Liu D, et al. Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1. MAbs. 2021;13(1):1914359. https://doi.org/10.1080/19420862.2021.1914359

15. Lallemand С, Liang F, Staub F, Simansour M, Vallette B, Huang L, et al. A novel system for the quantification of the ADCC activity of therapeutic antibodies. J Immunol Res. 2017;2017:1–19. https://doi.org/10.1155/2017/3908289

16. Wang L, Yu C, Yang Y, Gao K, Wang J. Development of a robust reporter gene assay to measure the bioactivity of anti-PD-1/anti-PD-L1 therapeutic antibodies. J Pharm Biomed Anal. 2017;145:447–53 https://doi.org/10.1016/j.jpba.2017.05.011

17. Alhazmi HA, Albratty M. Analytical techniques for the characterization and quantification of monoclonal antibodies. Pharmaceuticals (Basel). 2023;16(2):291. https://doi.org/10.3390/ph16020291

18. Bansal R, Dash R, Rathore AS. Impact of mAb aggregation on its biological activity: Rituximab as a case study. J Pharm Sci. 2020;109(9):2684–98. https://doi.org/10.1016/j.xphs.2020.05.015

19. Tada M, Ishii-Watabe A, Suzuki T, Kawasaki N. Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies. PLoS One. 2014;9(4):e95787. https://doi.org/10.1371/journal.pone.0095787

20. Geigert J. Quality attributes of a biopharmaceutical. In: Geigert J. The challenge of CMC regulatory compliance for biopharmaceuticals. Switzerland: Springer; 2019. P. 311–29.

21. Alpatova NA, Gaiderova LA, Yakovlev AK, Motuzova EV, Lysikova SL, Soldatov AA, Avdeeva ZhI. Peculiarities of determination of specific activity of biotechnological medicinal products. BIOpreparations. Prevention, diagnostics, treatment. 2017;17(1):13–26 (In Russ.). EDN: YHSSGL

22. Prior S, Hufton SE, Fox B, Dougall T, Rigsby P, Bristow A. International standards for monoclonal antibodies to support pre- and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximab. MAbs. 2018;10(1):129–42. https://doi.org/10.1080/19420862.2017.1386824

23. Rižner TL, Adamski J. It is high time to discontinue use of misidentified and contaminated cells: Guidelines for description and authentication of cell lines. J Steroid Biochem Mol Biol. 2018;182:1–3. https://doi.org/10.1016/j.jsbmb.2017.12.017

24. Melnikova EV, Merkulova OV, Merkulov VA, Olefir YuV, Ruchko SV, Bokovanov VE. Human cell line identification by typing of short tandem repeats: World practice. Russian Journal of Biopharmaceuticals. 2015;7(6):3–10 (In Russ.). EDN: VRRBXF

25. Khorolsky MD, Semenova IS, Melnikova EV, Olefir YuV. The use of short tandem repeat analysis for cell line authentication. BIOpreparations. Prevention, Diagnosis, Treatment. 2019;19(4):251–60 (In Russ.). https://doi.org/10.30895/2221-996X-2019-19-4-251-260

26. White JR, Abodeely M, Ahmed S, Debauve G, Johnson E, Meyer DM, et al. Best practices in bioassay development to support registration of biopharmaceuticals. Biotechniques. 2019;67(3):126–37. https://doi.org/10.2144/btn-2019-0031

27. Zimmermann H, Gerhard D, Dingermann T, Hothorn LA. Statistical aspects of design and validation of microtitre-plate-based linear and non-linear parallel in vitro bioassays. Biotechnol J. 2010;5(1):62–74. https://doi.org/10.1002/biot.200900146

28. Surowka M, Klein C. A pivotal decade for bispecific antibodies? MAbs. 2024;16(1):2321635. https://doi.org/10.1080/19420862.2024.2321635

29. Nie S, Wang Z, Moscoso-Castro M, D’Souza P, Lei C, Xu J, Gu J. Biology drives the discovery of bispecific antibodies as innovative therapeutics. Antib Ther. 2020;3(1):18–62. https://doi.org/10.1093/abt/tbaa003

30. Mohan N, Ayinde S, Peng H, Dutta S, Shen Y, Falkowski VM. Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies. Front Immunol. 2024;15:1376096. https://doi.org/10.3389/fimmu.2024.1376096

31. Lee HY, Contreras E, Register AC, Wu Q, Abadie K, Garcia K, et al. Development of a bioassay to detect T-cell-activating impurities for T-cell-dependent bispecific antibodies. Sci Rep. 2019;9(1):3900. https://doi.org/10.1038/s41598-019-40689-1

32. Lee HY, Schaefer G, Lesaca I, Lee CV, Wong PY, Jiang G. “Two-in-One” approach for bioassay selection for dual specificity antibodies. J Immunol Methods. 2017;448:74–9. https://doi.org/10.1016/j.jim.2017.05.011

33. Golovinskaya OV, Lysikova SL, Lebe-deva YuN, Alpatova NA, Movsesyants AA, Merkulov VA. Recom-mendations for the presentation of the methodology for assessing the biological (specific) activity of biotechnological drugs in regulatory documentation. BIOpreparations. Prevention, diagnostics, treatment. 2018;18(3):168–74 (In Russ.). https://doi.org/10.30895/2221-996X-2018-18-3-168-174